Asset 1

In Situ Hybridization (ISH)

Identify the precise localization of nucleic acids sequences within the nucleus.

Discovery’s In Situ Hybridization (ISH) services offer precise localization, sensitivity, and multiplexing, enabling comprehensive molecular analyses for drug and diagnostic development programs.

Discovery Advantages


Decades of experience developing, validating and applying biomarker assays throughout every stage of development for leading biotech and pharma clients.


A technology agnostic approach to enable an unbiased selection of the most suitable platforms .

Compliance & Quality

Specialty testing in CLIA-certified, CAP accredited, and GCLP compliant service laboratories to support concurrent clinical trials and regulatory submissions.

IVDR-compliant services with Health Institution status of Discovery’s laboratory in Germany confirmed by German Regional Council.

Global Harmonization

Global standardization and harmonization of assays including global clinical trial testing and our Biomarker Academy™ training programs with post-approval services.

Access to Clinical Specimens

Access to the world’s largest commercial biorepository to build optimal study cohorts.

Rapid Orthogonal Testing

Optimized multi-omic integration with clinical flow, cell biology, genomic, and proteomic services – all under one roof.

Technology Platforms

We use a technology agnostic approach so you can choose the right technology for your project. Our expert scientists work with you consultatively to make sure your study is designed to achieve optimal outcomes.


Dako / Agilent



Akoya PhenoImager™


Contact Us Today

Quick Links


Development and Clinical
Trial Solutions